Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial

BACKGROUND: Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overall...

Full description

Saved in:
Bibliographic Details
Main Authors: Combs, Stephanie E, Kieser, Meinhard, Rieken, Stefan, Habermehl, Daniel, Jäkel, Oliver, Haberer, Thomas, Nikoghosyan, Anna, Haselmann, Renate, Unterberg, Andreas, Wick, Wolfgang, Debus, Jürgen
Format: Artigo
Language:Inglês
Published: BioMed Central 2010
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2944178/
https://ncbi.nlm.nih.gov/pubmed/20819220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-478
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items